[Comparative safety evaluation of first- and second-line therapy with carboplatin + paclitaxel for advanced non-small cell lung cancer].

The study was carried out to compare the incidence of hematological toxicity between 14 cases with CDDP+VNR as first line therapy followed by CBDCA+PTX as second-line therapy, and 21 cases with CBDCA+PTX as first-line therapy for nonsmall cell lung cancer. The incidences of thrombocytopenia were 78. 6% in the second-line and 42.